a process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal -, or polyclonal -, monomeric , dimeric , or polymeric iga . joining secretory component to the iga limits oral administration degradation . formulating agents are mixed with the monomeric , dimeric , or polymeric iga to yield a dosing form of a capsule , tablet , and a suppository . the therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating .